Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Dow, Exelixis pursue drugs from plants
January 9, 2006
| A version of this story appeared in
Volume 84, Issue 2
Dow AgroSciences, in partnership with the University of Melbourne, has received a grant from the Australian Research Council to pursue development of plant-derived production systems for an avian flu vaccine. Meanwhile, Exelixis Plant Sciences and Washington State University Research Foundation have signed a licensing agreement under which Exelixis will use its expertise in cell production and metabolic engineering to advance WSURF's technology for producing paclitaxel and other pharmaceutical taxanes from plant cell culture.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter